YANG Dajun,Chairman of PhIRDA Drug R&D Specialty Committee, Chairman of the Board & CEO of Ascentage Pharma
13:30 PM-14:00 PM
项目1
Project 1
项目第一阶段 13:30 PM-13:45 PM
绿原酸作用靶点发现与抗肿瘤作用
Target Discovery and Anti-tumor Effect of Chlorogenic Acid
陈晓光,中国药促会药物研发专业委员会委员、中国医学科学院药物研究所药理室主任
CHEN Xiaoguang, Member of PhIRDA Drug R&D Specialty Committee、Director, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College
项目第二阶段 13:45 PM-14:00 PM
注射用绿原酸治疗复发胶质母细胞瘤I/II期临床试验进展汇报
Evaluation of Chlorogenic Acid for Injection in the Treatment of Recurrent Glioblastoma
ZHANG Dan,Vice-Chairman of PhIRDA Drug R&D Specialty Committee,Foreign Academician of Russian Academy of Engineering, Co-founder and Chief Strategy Officer of ClinChoice
15:15 PM-15:40 PM
项目5
Project 5
HTD1801改善二型糖尿病合并脂肪肝患者心血管代谢的临床2期试验结果
Phase 2 Trial Results of HTD1801 Improving Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Fatty Liver Diseases
刘利平, 深圳君圣泰生物技术有限公司创始人兼首席执行官
LIU Liping, Founder&CEO, Shenzhen HighTide Biopharmaceutical Ltd.
15:40 PM-16:05 PM
项目6
Project 6
糖尿病创新药苏帕鲁肽的I期II期临床数据汇报
Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Supaglutide, a Novel Weekly Dosing GLP-1 Based Therapy
王庆华, 国家特聘专家、上海银诺医药技术有限公司董事长兼CEO
WANG Qinghua,State Specially Recruited Experts, CEO & General Manager of Innogen Pharmaceutical Technology Co., Ltd.
16:05 PM-16:30 PM
项目7
Project 7
SHR0302 JAK1 抑制剂治疗斑秃的II期临床试验结果
Positive Topline Phase 2 Results for SHR0302, a Selective JAK1 Inhibitor, for Treatment of Patients with Alopecia Areata
First in Human Phase Ⅰ Study of PI3K Dual β/δ Inhibitor CVL237 in Patients with B Cell Lymphoma and Potential Treatment for Bruton Tyrosine Kinase Resistance
张虹, 甫康药业首席医学官
Helena ZHANG, Chief Medical Officer, Convalife
16:55 PM-17:20 PM
项目9
Project 9
晚期实体肿瘤新药PENAO的首个人体І期临床试验
The First-in-Human Phase I Clinical Trial of PENAO in Advanced Solid Tumors
贾正虎, 贝罗尼集团副总裁
JIA Zhenghu, Vice President of Beroni Group Limited